BH3:FRA
PTC Therapeutics, Inc.
€ 66.56
arrow_downward
-0.75%(-0.50) 1D
7-р сарын 17, 22:00:00 (GMT+2) · EUR
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BH3...
Open
€ 66.56
High
€ 66.56
Low
€ 66.56
Mkt. cap
6.52 тэрбум
Avg. vol.
0.00
Volume
0.00
52-wk high
€ 77.02
52-wk low
€ 36.60
No. of employees
991
Open
€ 66.56
High
€ 66.56
Low
€ 66.56
Mkt. cap
6.52 тэрбум
Avg. vol.
0.00
Volume
0.00
52-wk high
€ 77.02
52-wk low
€ 36.60
No. of employees
991
News stories
From sources across the web
Investing.com Canada
·
2 өдрийн өмнө
PTC Therapeutics CFO Pierre Gravier sells $280,742 in shares By Investing.com
https://www.dars.gov.et/
·
3 долоо хоногийн өмнө
PTC Therapeutics Q1 2026 Earnings: EPS Surprise of 93.75% as Loss Narrows - New Analyst Coverage
Profile
PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control mechanisms in orphan diseases.
In September 2009, PTC entered into an agreement with Roche for the development of orally bioavailable small molecules for central nervous system diseases. PTC acquired the Bio-e platform in 2019. Wikipedia
About PTC Therapeutics, Inc.
CEOMatthew B. Klein
Employees991
Founded1998 оны 1-р сарын 1
HeadquartersWarren, Нью Жерси, Америкийн Нэгдсэн Улс
Sector-
Websiteptcbio.com
AI content may include mistakes. Learn more